Anacaulase

(NexoBrid®)

NexoBrid®

Drug updated on 11/15/2023

Dosage FormGel (topical; 8.8%)
Drug ClassProteolytic enzymes
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • For removal of eschar in adults with deep partial thickness and/or full thickness thermal burns.

Product Monograph / Prescribing Information

Document TitleYearSource
NexoBrid (anacaulase-bcdb) Prescribing Information. 2023Vericel Corporation, Cambridge, MA

Systematic Reviews / Meta-Analyses